Raymond James Upgrades Oncolytics Biotech (TSE:ONC) to “Moderate Buy”

Oncolytics Biotech (TSE:ONC) was upgraded by Raymond James to a “moderate buy” rating in a research note issued on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.

Oncolytics Biotech Trading Down 2.1 %

Shares of ONC opened at C$1.38 on Thursday. Oncolytics Biotech has a 12-month low of C$1.15 and a 12-month high of C$2.32. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The firm has a market capitalization of C$106.07 million, a price-to-earnings ratio of -3.63 and a beta of 1.35. The stock’s 50-day moving average price is C$1.50 and its 200 day moving average price is C$1.45.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.